Abstract PO1-28-08: The Efficacy and Safety Results of Neoadjuvant Phase II study of Anlotinib plus Sintilimab Combined with Chemotherapy in Triple-negative Breast Cancer (NeoSACT)
Liulu Zhang(Southwest Medical University), Kun Wang(Chinese Academy of Sciences), Hongfei Gao(Guangdong Academy of Medical Sciences), Teng Zhu(Guangdong Academy of Medical Sciences), Ciqiu Yang(Guangdong Academy of Medical Sciences), Mei Yang(Tongji University)
Cited by 1
Related Papers
Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells
|Molecular Cancer|2011|700
MiR-21 Indicates Poor Prognosis in Tongue Squamous Cell Carcinomas as an Apoptosis Inhibitor
|Clinical Cancer Research|2009|435
MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1
|Oncogene|2011|248
Increased serum IL-17 and IL-23 in the patient with ankylosing spondylitis
|Clinical Rheumatology|2010|230